MBX Biosciences (MBX) announced the appointment of Steve Hoerter as an independent director to the Company’s Board of Directors. Hoerter previously served as President, CEO and Director of Deciphera Pharmaceuticals until its $2.4 billion acquisition by Ono Pharmaceutical in 2024.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBX:
- MBX Biosciences, Inc.: Promising Outlook with Strong Financials and Key Catalysts
- PepsiCo to acquire poppi, Guess receives WHP offer: Morning Buzz
- MBX Biosciences reports Q4 EPS (47c), consensus (59c)
- MBX Biosciences announces additions to its leadership team
- MBX Biosciences completes enrollment in Phase 2 Avail trial of MBX 2109